Antimutagenic activity of ipriflavone against the DNA-damage induced by cyclophosphamide in mice

- Antimutagenicity of ipriflavone was evaluated through mice bone marrow micronucleus test.
- Ipriflavone was shown to be antimutagenic and anticytotoxic activities.
- Reduced the mutagenicity and cytotoxicity induced by cyclophosphamide.
- Further studies are needed in order to validate the safety of ipriflavone as medicine.

In the present study we evaluated the potential of ipriflavone against the cytotoxic and mutagenic effects induced by cyclophosphamide chemotherapeutic agent in bone marrow cells of mice, using the micronucleus assay in vivo on cells of bone marrow. The study was performed following three protocols: pre-treatment, simultaneous treatment and post treatment. The results demonstrated that ipriflavone has a protective effect against mutagenicity induced by cyclophosphamide in the pre-treatment and post-treatment and against the cytotoxicity in all treatments. There was variation between the genders in some of the experimental groups. To evaluate their possible mechanisms of action, it was performed the DPPH assay, which showed no ability to donate hydrogens, suggesting that it acts through other mechanisms. Due to its ability to prevent chromosomal damage, ipriflavone is likely to open an interest field concerning its possible the use in clinical applications.